Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
13.01
-0.64 (-4.69%)
Nov 20, 2026, 11:50 AM EST - Market open
Biohaven Employees
Biohaven had 274 employees as of December 31, 2025. The number of employees increased by 18 or 7.03% compared to the previous year. That makes Biohaven the 24,585th largest employer in the world and 3,135th in the United States.
Employees
274
Change (1Y)
18
Growth (1Y)
7.03%
Revenue / Employee
n/a
Profits / Employee
-$1,980,573
Market Cap
1.97B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 274 | 18 | 7.03% |
| Dec 31, 2024 | 256 | 17 | 7.11% |
| Dec 31, 2023 | 239 | 37 | 18.32% |
| Dec 31, 2022 | 202 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Replimune Group | 465 |
| Maravai LifeSciences Holdings | 410 |
| Vera Therapeutics | 362 |
| Harmony Biosciences Holdings | 293 |
| Immunome | 267 |
| Septerna | 134 |
| Aurinia Pharmaceuticals | 128 |
BHVN News
- 1 day ago - Biohaven’s BHV-1530 shows clinical activity, confirmed responses in cancer study - TheFly
- 1 day ago - Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026 - PRNewsWire
- 1 day ago - Biohaven price target raised to $35 from $14 at JPMorgan - TheFly
- 15 days ago - Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting - PRNewsWire
- 17 days ago - Biohaven price target raised to $21 from $19 at Morgan Stanley - TheFly
- 21 days ago - Biohaven price target raised to $32 from $21 at Canaccord - TheFly
- 21 days ago - Biohaven reports Q3 adjusted EPS (73c) vs. ($1.47) last year - TheFly
- 21 days ago - Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results - PRNewsWire